Ordering

Prescribed around the world—and now in your office.

Give your patients another option to temporarily improve moderate to severe glabellar lines—order Dysport® today by calling 1-844-GALDERM, or contact your sales account manager for more information.

Please note: to order Dysport, you must be a licensed healthcare professional within the United States.

Find a Specialist feature

Information about your Find a Specialist feature listing

Galderma Laboratories, L.P. is pleased to announce that the Find a Specialist feature on DysportUSA.com now makes it easier than ever for website visitors to locate and contact you regarding treatment with Dysport.

All you have to do to remain listed on the DysportUSA.com Find a Specialist feature is place an order for Dysport a minimum of every 6 months.


Contact your sales account manager today about your listing

To discuss your product needs and your Find a Specialist eligibility status, please contact your Galderma Laboratories, L.P. sales account manager today or Galderma Laboratories, L.P. customer service at gss@galdermaservices.com.

Remember: There’s only one FDA-approved Dysport. Be sure to check the packaging of your product to make sure it’s authentic. Find out how.

See below for Dysport Important Safety Information and Full Prescribing Information, including Boxed Warning.

IMPORTANT SAFETY INFORMATION

Indication: Dysport® (abobotulinumtoxinA) for Injection is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with procerus and corrugator muscle activity in adult patients ˂65 years of age.

Distant Spread of Toxin Effect

Postmarketing reports indicate that the effects of Dysport and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses, including upper limb spasticity in children, and in approved indications, cases of spread of effect have been reported at doses comparable to or lower than the maximum recommended total dose.

Contraindications

Warnings and Precautions

Adverse Reaction

Drug Interactions

Use in Specific Populations

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see Dysport Full Prescribing Information, including Medication Guide.